Literature DB >> 19161099

Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman.

A Mohammadi1, Z S Nassor, T Behlim, E Mohammadi, R Govindarajan, A Al Maniri, R A Smego.   

Abstract

We conducted an epidemiological and cost analysis for all 13 patients diagnosed with multaidrug-resistant tuberculosis (11 pulmonary, 2 extrapulmonary) in Oman from January 2000 to October 2005. The disease was secondary, or acquired, in 12 of 13 patients. A total of 140 contacts were screened (mean 10.8 persons per patient), but contact tracing revealed no secondary cases. The mean number of drugs that TB isolates were resistant to was 2.8 (range 2-5). A mean of 4.7 drugs were given to patients, the mean length of therapy was 8 months and all patients were cured. The cost of medications for these multidrug-resistant cases was 14 to 29 times higher than that for the standard drug-sensitive TB regimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19161099

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  4 in total

1.  Epidemiology of Drug-resistant Tuberculosis in a Tertiary Care Center in Oman, 2006-2015.

Authors:  Zied Gaifer; Ahmed Babiker; Dawar Rizavi
Journal:  Oman Med J       Date:  2017-01

2.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

3.  Transmission pattern of drug-resistant tuberculosis and its implication for tuberculosis control in eastern rural China.

Authors:  Yi Hu; Barun Mathema; Weili Jiang; Barry Kreiswirth; Weibing Wang; Biao Xu
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

4.  Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.

Authors:  Miranda W Langendam; Edine W Tiemersma; Marieke J van der Werf; Andreas Sandgren
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.